186 filings
8-K
SPNC
Spectranetics Corp
14 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
SPNC
Spectranetics Corp
9 Aug 17
Termination of a Material Definitive Agreement
12:00am
8-K
SPNC
Spectranetics Corp
3 Aug 17
Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million
12:00am
8-K
SPNC
Spectranetics Corp
26 Jul 17
Regulation FD Disclosure
12:00am
8-K
SPNC
Spectranetics Corp
30 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
t5s83evwvb4
14 Jun 17
Other Events
12:00am
8-K
u25ubj
14 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
7ss2bd
9 Jun 17
Spectranetics Announces $140 Million Debt Refinancing
12:00am
8-K
i3k4cktc7n57 mtlkam0
27 Apr 17
Spectranetics Reports First Quarter 2017 Revenue of $69.7 million
12:00am
8-K
vxleecpttd943lenj1t8
23 Feb 17
Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million
12:00am
8-K
hbqrn5
24 Jan 17
Regulation FD Disclosure
12:00am
8-K
35pqf8rc
20 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
r924 p4qt29bc
11 Jan 17
Spectranetics Names Scott Hutton as General Manager, Vascular Intervention
12:00am
8-K
1hhkozyvmy2qgcwcagp
11 Jan 17
Regulation FD Disclosure
12:00am
8-K
9oekk1ijwqvqlk
14 Nov 16
Regulation FD Disclosure
12:00am
8-K
5dnjgf
2 Nov 16
Spectranetics Files PMA Application for FDA Approval of the Stellarex™ Drug-Coated Balloon
12:00am
8-K
aikpula
2 Nov 16
Stellarex™ ILLUMENATE Pivotal Results are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials
12:00am
8-K
3dhcss3se4x8dch1
27 Oct 16
Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million
12:00am
8-K
0iokl1m
11 Aug 16
First Randomized Trial of the Stellarex™ Drug-coated Balloon Presented at the Amputation Prevention Symposium
12:00am
8-K
g37hhskk
10 Aug 16
Other Events
12:00am